Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 125 entries
Sorted by: Best Match Show Resources per page
Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease.

Movement disorders clinical practice

Zimansky L, Muntean ML, Leha A, Mollenhauer B, Trenkwalder C, Sixel-Döring F.
PMID: 33977115
Mov Disord Clin Pract. 2021 Mar 10;8(4):534-540. doi: 10.1002/mdc3.13168. eCollection 2021 May.

BACKGROUND: Rapid eye movement (REM) sleep behavior disorder (RBD) is associated with neurodegenerative diseases; however, few longitudinal studies assess the individual evolution of RBD and REM sleep without atonia (RWA) in Parkinson's disease (PD).OBJECTIVES: We aimed to evaluate RBD...

Cite
Zimansky L, Muntean ML, Leha A, et al. Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease. Mov Disord Clin Pract. 2021;8(4):534-540doi: 10.1002/mdc3.13168.
Zimansky, L., Muntean, M. L., Leha, A., Mollenhauer, B., Trenkwalder, C., & Sixel-Döring, F. (2021). Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease. Movement disorders clinical practice, 8(4), 534-540. https://doi.org/10.1002/mdc3.13168
Zimansky, Larissa, et al. "Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease." Movement disorders clinical practice vol. 8,4 (2021): 534-540. doi: https://doi.org/10.1002/mdc3.13168
Zimansky L, Muntean ML, Leha A, Mollenhauer B, Trenkwalder C, Sixel-Döring F. Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease. Mov Disord Clin Pract. 2021 Mar 10;8(4):534-540. doi: 10.1002/mdc3.13168. eCollection 2021 May. PMID: 33977115; PMCID: PMC8088113.
Copy Download .nbib Format: NLM
Influence of the PO.

Physical chemistry chemical physics : PCCP

Henkel P, Janek J, Mollenhauer D.
PMID: 34591051
Phys Chem Chem Phys. 2021 Oct 13;23(39):22567-22588. doi: 10.1039/d1cp01294k.

The potential of mobile applications for digital networking is constantly increasing. A key challenge is to ensure a reliable and long-term power supply. One possible solution is the use of all-solid-state thin-film lithium batteries which use amorphous lithium phosphorus...

Cite
Henkel P, Janek J, Mollenhauer D. Influence of the PO. Phys Chem Chem Phys. 2021;23(39):22567-22588doi: 10.1039/d1cp01294k.
Henkel, P., Janek, J., & Mollenhauer, D. (2021). Influence of the PO. Physical chemistry chemical physics : PCCP, 23(39), 22567-22588. https://doi.org/10.1039/d1cp01294k
Henkel, Pascal, et al. "Influence of the PO." Physical chemistry chemical physics : PCCP vol. 23,39 (2021): 22567-22588. doi: https://doi.org/10.1039/d1cp01294k
Henkel P, Janek J, Mollenhauer D. Influence of the PO. Phys Chem Chem Phys. 2021 Oct 13;23(39):22567-22588. doi: 10.1039/d1cp01294k. PMID: 34591051.
Copy Download .nbib Format: NLM
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.

JAMA neurology

Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D.
PMID: 34807233
JAMA Neurol. 2022 Jan 01;79(1):32-37. doi: 10.1001/jamaneurol.2021.4222.

IMPORTANCE: Plasma phosphorylated tau (p-tau) has proven to be an accurate biomarker for Alzheimer disease (AD) pathologic characteristics, offering a less expensive and less invasive alternative to cerebrospinal fluid (CSF) and positron emission tomography biomarkers for amyloid-β and tau....

Cite
Gonzalez MC, Ashton NJ, Gomes BF, et al. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurol. 2022;79(1):32-37doi: 10.1001/jamaneurol.2021.4222.
Gonzalez, M. C., Ashton, N. J., Gomes, B. F., Tovar-Rios, D. A., Blanc, F., Karikari, T. K., Mollenhauer, B., Pilotto, A., Lemstra, A., Paquet, C., Abdelnour, C., Kramberger, M. G., Bonanni, L., Vandenberghe, R., Hye, A., Blennow, K., Zetterberg, H., Aarsland, D. (2022). Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA neurology, 79(1), 32-37. https://doi.org/10.1001/jamaneurol.2021.4222
Gonzalez, Maria C, et al. "Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies." JAMA neurology vol. 79,1 (2022): 32-37. doi: https://doi.org/10.1001/jamaneurol.2021.4222
Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurol. 2022 Jan 01;79(1):32-37. doi: 10.1001/jamaneurol.2021.4222. PMID: 34807233; PMCID: PMC8609462.
Copy Download .nbib Format: NLM
An emerging spectrum of variants and clinical features in .

Channels (Austin, Tex.)

Miller JP, Moldenhauer HJ, Keros S, Meredith AL.
PMID: 34224328
Channels (Austin). 2021 Dec;15(1):447-464. doi: 10.1080/19336950.2021.1938852.

No abstract available.

Cite
Miller JP, Moldenhauer HJ, Keros S, et al. An emerging spectrum of variants and clinical features in . Channels (Austin). 2021;15(1):447-464doi: 10.1080/19336950.2021.1938852.
Miller, J. P., Moldenhauer, H. J., Keros, S., & Meredith, A. L. (2021). An emerging spectrum of variants and clinical features in . Channels (Austin, Tex.), 15(1), 447-464. https://doi.org/10.1080/19336950.2021.1938852
Miller, Jacob P, et al. "An emerging spectrum of variants and clinical features in ." Channels (Austin, Tex.) vol. 15,1 (2021): 447-464. doi: https://doi.org/10.1080/19336950.2021.1938852
Miller JP, Moldenhauer HJ, Keros S, Meredith AL. An emerging spectrum of variants and clinical features in . Channels (Austin). 2021 Dec;15(1):447-464. doi: 10.1080/19336950.2021.1938852. PMID: 34224328; PMCID: PMC8259716.
Copy Download .nbib Format: NLM
The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease.

Movement disorders clinical practice

Halsband C, Zapf A, Sixel-Döring F, Trenkwalder C, Mollenhauer B.
PMID: 30009211
Mov Disord Clin Pract. 2018 Mar 01;5(2):171-176. doi: 10.1002/mdc3.12591. eCollection 2018.

BACKGROUND: Rapid eye movement (REM) sleep behavior disorder (RBD) is one of the most specific prodromal indicators for Parkinson's disease (PD).OBJECTIVES: To test the validity of the RBD-Screening Questionnaire (RBDSQ) in assessing RBD in early PD.METHODS: The RBDSQ was...

Cite
Halsband C, Zapf A, Sixel-Döring F, et al. The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease. Mov Disord Clin Pract. 2018;5(2):171-176doi: 10.1002/mdc3.12591.
Halsband, C., Zapf, A., Sixel-Döring, F., Trenkwalder, C., & Mollenhauer, B. (2018). The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease. Movement disorders clinical practice, 5(2), 171-176. https://doi.org/10.1002/mdc3.12591
Halsband, Claire, et al. "The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease." Movement disorders clinical practice vol. 5,2 (2018): 171-176. doi: https://doi.org/10.1002/mdc3.12591
Halsband C, Zapf A, Sixel-Döring F, Trenkwalder C, Mollenhauer B. The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease. Mov Disord Clin Pract. 2018 Mar 01;5(2):171-176. doi: 10.1002/mdc3.12591. eCollection 2018. PMID: 30009211; PMCID: PMC6033034.
Copy Download .nbib Format: NLM
Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Alzheimer's & dementia (Amsterdam, Netherlands)

Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Piqué A, Schmitz M, Lehmann S, Teunissen C, Blennow K, Zetterberg H, Mollenhauer B, Zerr I, Llorens F.
PMID: 30294658
Alzheimers Dement (Amst). 2018 Jul 07;10:461-470. doi: 10.1016/j.dadm.2018.06.005. eCollection 2018.

INTRODUCTION: Cerebrospinal fluid α-synuclein level is increased in sporadic Creutzfeldt-Jakob disease cases. However, the clinical value of this biomarker remains to be established. In this study, we have addressed the clinical validation parameters and the interlaboratory reproducibility by using...

Cite
Kruse N, Heslegrave A, Gupta V, et al. Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. Alzheimers Dement (Amst). 2018;10:461-470doi: 10.1016/j.dadm.2018.06.005.
Kruse, N., Heslegrave, A., Gupta, V., Foiani, M., Villar-Piqué, A., Schmitz, M., Lehmann, S., Teunissen, C., Blennow, K., Zetterberg, H., Mollenhauer, B., Zerr, I., & Llorens, F. (2018). Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. Alzheimer's & dementia (Amsterdam, Netherlands), 10461-470. https://doi.org/10.1016/j.dadm.2018.06.005
Kruse, Niels, et al. "Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 10 (2018): 461-470. doi: https://doi.org/10.1016/j.dadm.2018.06.005
Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Piqué A, Schmitz M, Lehmann S, Teunissen C, Blennow K, Zetterberg H, Mollenhauer B, Zerr I, Llorens F. Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. Alzheimers Dement (Amst). 2018 Jul 07;10:461-470. doi: 10.1016/j.dadm.2018.06.005. eCollection 2018. PMID: 30294658; PMCID: PMC6171371.
Copy Download .nbib Format: NLM
Photosynthetic carbon assimilation in Geosiphon pyriforme (Kützing) F. v. Wettstein, an endosymbiotic association of fungus and cyanobacterium.

Planta

Kluge M, Mollenhauer D, Mollenhauer R.
PMID: 24186411
Planta. 1991 Oct;185(3):311-5. doi: 10.1007/BF00201049.

Geosiphon pyriforme, an endosymbiotic association between a fungus and the cyanobacterium Nostoc, was shown by tracer studies to acquire carbon photosynthetically from CO2 or bicarbonate. The organism also fixes inorganic carbon in darkness, at lower rates than in the...

Cite
Kluge M, Mollenhauer D, Mollenhauer R. Photosynthetic carbon assimilation in Geosiphon pyriforme (Kützing) F. v. Wettstein, an endosymbiotic association of fungus and cyanobacterium. Planta. 1991;185(3):311-5doi: 10.1007/BF00201049.
Kluge, M., Mollenhauer, D., & Mollenhauer, R. (1991). Photosynthetic carbon assimilation in Geosiphon pyriforme (Kützing) F. v. Wettstein, an endosymbiotic association of fungus and cyanobacterium. Planta, 185(3), 311-5. https://doi.org/10.1007/BF00201049
Kluge, M, et al. "Photosynthetic carbon assimilation in Geosiphon pyriforme (Kützing) F. v. Wettstein, an endosymbiotic association of fungus and cyanobacterium." Planta vol. 185,3 (1991): 311-5. doi: https://doi.org/10.1007/BF00201049
Kluge M, Mollenhauer D, Mollenhauer R. Photosynthetic carbon assimilation in Geosiphon pyriforme (Kützing) F. v. Wettstein, an endosymbiotic association of fungus and cyanobacterium. Planta. 1991 Oct;185(3):311-5. doi: 10.1007/BF00201049. PMID: 24186411.
Copy Download .nbib Format: NLM
Small bowel pleomorphic liposarcoma: a rare cause of gastrointestinal bleeding.

Case reports in gastrointestinal medicine

Nennstiel S, Mollenhauer M, Schlag C, Becker V, Neu B, Hüser N, Gertler R, Schmid RM, von Delius S.
PMID: 25161780
Case Rep Gastrointest Med. 2014;2014:391871. doi: 10.1155/2014/391871. Epub 2014 Aug 04.

In this case report we present a 60-year-old male patient with overt midgastrointestinal bleeding of a primary ileal pleomorphic liposarcoma diagnosed by video capsule endoscopy (VCE). Clinical work-up for final diagnosis and the pathological background of this uncommon tumorous...

Cite
Nennstiel S, Mollenhauer M, Schlag C, et al. Small bowel pleomorphic liposarcoma: a rare cause of gastrointestinal bleeding. Case Rep Gastrointest Med. 2014;2014:391871doi: 10.1155/2014/391871.
Nennstiel, S., Mollenhauer, M., Schlag, C., Becker, V., Neu, B., Hüser, N., Gertler, R., Schmid, R. M., & von Delius, S. (2014). Small bowel pleomorphic liposarcoma: a rare cause of gastrointestinal bleeding. Case reports in gastrointestinal medicine, 2014391871. https://doi.org/10.1155/2014/391871
Nennstiel, Simon, et al. "Small bowel pleomorphic liposarcoma: a rare cause of gastrointestinal bleeding." Case reports in gastrointestinal medicine vol. 2014 (2014): 391871. doi: https://doi.org/10.1155/2014/391871
Nennstiel S, Mollenhauer M, Schlag C, Becker V, Neu B, Hüser N, Gertler R, Schmid RM, von Delius S. Small bowel pleomorphic liposarcoma: a rare cause of gastrointestinal bleeding. Case Rep Gastrointest Med. 2014;2014:391871. doi: 10.1155/2014/391871. Epub 2014 Aug 04. PMID: 25161780; PMCID: PMC4137735.
Copy Download .nbib Format: NLM
Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia.

International journal of Alzheimer's disease

Bibl M, Esselmann H, Lewczuk P, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Mollenhauer B.
PMID: 20862375
Int J Alzheimers Dis. 2010 Aug 24;2010. doi: 10.4061/2010/761571.

We studied the diagnostic value of CSF Aβ42/tau versus low Aβ1-42% and high Aβ1-40(ox)% levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21...

Cite
Bibl M, Esselmann H, Lewczuk P, et al. Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int J Alzheimers Dis. 2010;2010doi: 10.4061/2010/761571.
Bibl, M., Esselmann, H., Lewczuk, P., Trenkwalder, C., Otto, M., Kornhuber, J., Wiltfang, J., & Mollenhauer, B. (2010). Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. International journal of Alzheimer's disease, 2010. https://doi.org/10.4061/2010/761571
Bibl, Mirko, et al. "Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia." International journal of Alzheimer's disease vol. 2010 (2010). doi: https://doi.org/10.4061/2010/761571
Bibl M, Esselmann H, Lewczuk P, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Mollenhauer B. Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int J Alzheimers Dis. 2010 Aug 24;2010. doi: 10.4061/2010/761571. PMID: 20862375; PMCID: PMC2938459.
Copy Download .nbib Format: NLM
Ribosome particles in corn mitochondria.

Plant physiology

Wilson RH, Hanson JB, Mollenhauer HH.
PMID: 16656982
Plant Physiol. 1968 Nov;43(11):1874-7. doi: 10.1104/pp.43.11.1874.

No abstract available.

Cite
Wilson RH, Hanson JB, Mollenhauer HH. Ribosome particles in corn mitochondria. Plant Physiol. 1968;43(11):1874-7doi: 10.1104/pp.43.11.1874.
Wilson, R. H., Hanson, J. B., & Mollenhauer, H. H. (1968). Ribosome particles in corn mitochondria. Plant physiology, 43(11), 1874-7. https://doi.org/10.1104/pp.43.11.1874
Wilson, R H, et al. "Ribosome particles in corn mitochondria." Plant physiology vol. 43,11 (1968): 1874-7. doi: https://doi.org/10.1104/pp.43.11.1874
Wilson RH, Hanson JB, Mollenhauer HH. Ribosome particles in corn mitochondria. Plant Physiol. 1968 Nov;43(11):1874-7. doi: 10.1104/pp.43.11.1874. PMID: 16656982; PMCID: PMC1087093.
Copy Download .nbib Format: NLM
Phosphine passivated gold clusters: how charge transfer affects electronic structure and stability.

Physical chemistry chemical physics : PCCP

Mollenhauer D, Gaston N.
PMID: 27711516
Phys Chem Chem Phys. 2016 Nov 02;18(43):29686-29697. doi: 10.1039/c6cp04562f.

A systematic evaluation of small phosphine ligand-protected gold clusters with six to nine gold atoms using density functional theory with dispersion correction has been performed in order to understand the major factors determining stability, including its size, shape, and...

Cite
Mollenhauer D, Gaston N. Phosphine passivated gold clusters: how charge transfer affects electronic structure and stability. Phys Chem Chem Phys. 2016;18(43):29686-29697doi: 10.1039/c6cp04562f.
Mollenhauer, D., & Gaston, N. (2016). Phosphine passivated gold clusters: how charge transfer affects electronic structure and stability. Physical chemistry chemical physics : PCCP, 18(43), 29686-29697. https://doi.org/10.1039/c6cp04562f
Mollenhauer, Doreen, and Gaston, Nicola. "Phosphine passivated gold clusters: how charge transfer affects electronic structure and stability." Physical chemistry chemical physics : PCCP vol. 18,43 (2016): 29686-29697. doi: https://doi.org/10.1039/c6cp04562f
Mollenhauer D, Gaston N. Phosphine passivated gold clusters: how charge transfer affects electronic structure and stability. Phys Chem Chem Phys. 2016 Nov 02;18(43):29686-29697. doi: 10.1039/c6cp04562f. PMID: 27711516.
Copy Download .nbib Format: NLM
Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned.

Frontiers in aging neuroscience

Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, Behnke S, Berendse HW, Bloem BR, Burn D, Dodel R, Grosset DG, Hu M, Kasten M, Krüger R, Moccia M, Mollenhauer B, Oertel W, Suenkel U, Walter U, Wirdefeldt K, Liepelt-Scarfone I, Maetzler W, Berg D.
PMID: 27445791
Front Aging Neurosci. 2016 Jun 22;8:147. doi: 10.3389/fnagi.2016.00147. eCollection 2016.

A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical onset of Parkinson's disease (PD). Studies have identified several different prodromal markers that may have the potential to predict the conversion from healthy to clinical PD...

Cite
Heinzel S, Roeben B, Ben-Shlomo Y, et al. Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Front Aging Neurosci. 2016;8:147doi: 10.3389/fnagi.2016.00147.
Heinzel, S., Roeben, B., Ben-Shlomo, Y., Lerche, S., Alves, G., Barone, P., Behnke, S., Berendse, H. W., Bloem, B. R., Burn, D., Dodel, R., Grosset, D. G., Hu, M., Kasten, M., Krüger, R., Moccia, M., Mollenhauer, B., Oertel, W., Suenkel, U., Walter, U., Wirdefeldt, K., Liepelt-Scarfone, I., Maetzler, W., & Berg, D. (2016). Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Frontiers in aging neuroscience, 8147. https://doi.org/10.3389/fnagi.2016.00147
Heinzel, Sebastian, et al. "Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned." Frontiers in aging neuroscience vol. 8 (2016): 147. doi: https://doi.org/10.3389/fnagi.2016.00147
Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, Behnke S, Berendse HW, Bloem BR, Burn D, Dodel R, Grosset DG, Hu M, Kasten M, Krüger R, Moccia M, Mollenhauer B, Oertel W, Suenkel U, Walter U, Wirdefeldt K, Liepelt-Scarfone I, Maetzler W, Berg D. Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Front Aging Neurosci. 2016 Jun 22;8:147. doi: 10.3389/fnagi.2016.00147. eCollection 2016. PMID: 27445791; PMCID: PMC4916171.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 125 entries